Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION: Phase II single-arm study of tepotinib in advanced NSCLC with METex14 skipping or MET amplification
2015-005696-24Phase 2Active
- Sponsor
- Merck KGaA
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Primary endpoint: Objective response rate (central assessment). Started Apr 2016; status: active.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-005696-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005696-24.